Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $21 from $23 and keeps a Buy rating on the shares. The firm remains “enthusiastic” about ENTR-601-44 and ENTR-601-45 following Entrada’s Q1 report.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating
- Entrada Therapeutics reports Q1 EPS (42c), consensus (77c)
- Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals
- Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment
- Entrada Therapeutics Gains UK Approval for DMD Study